BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23733758)

  • 1. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.
    Peters S; Michielin O; Zimmermann S
    J Clin Oncol; 2013 Jul; 31(20):e341-4. PubMed ID: 23733758
    [No Abstract]   [Full Text] [Related]  

  • 2. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib.
    Gautschi O; Peters S; Zoete V; Aebersold-Keller F; Strobel K; Schwizer B; Hirschmann A; Michielin O; Diebold J
    Lung Cancer; 2013 Nov; 82(2):365-7. PubMed ID: 24035431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
    Robinson SD; O'Shaughnessy JA; Cowey CL; Konduri K
    Lung Cancer; 2014 Aug; 85(2):326-30. PubMed ID: 24888229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.
    El Karak F; Assi T; Kourie HR; El Rassy E; Chebib R; Ghor M; Tabchi S
    Int J Clin Exp Pathol; 2015; 8(3):3294-8. PubMed ID: 26045855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
    Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
    Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.
    Gautschi O; Pauli C; Strobel K; Hirschmann A; Printzen G; Aebi S; Diebold J
    J Thorac Oncol; 2012 Oct; 7(10):e23-4. PubMed ID: 22743296
    [No Abstract]   [Full Text] [Related]  

  • 7. Eccrine squamous syringometaplasia in sites of radiation recall secondary to vemurafenib therapy for BRAF-mutated carcinoma.
    Moioli EK; Ligtenberg KG; Kenkare S; Shea CR; Soltani K
    J Dermatol; 2016 Oct; 43(10):1233-1234. PubMed ID: 27094584
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-Term Survival of a Patient With Non-Small-Cell Lung Cancer Harboring a V600E Mutation in the BRAF Oncogene.
    Myall NJ; Neal JW; Cho-Phan CD; Zhou LY; Stehr H; Zhou L; Diehn M; Wakelee HA
    Clin Lung Cancer; 2016 Mar; 17(2):e17-21. PubMed ID: 26776917
    [No Abstract]   [Full Text] [Related]  

  • 9. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
    Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
    J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
    [No Abstract]   [Full Text] [Related]  

  • 10. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
    Kaplan HG
    J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained Response to Vemurafenib in a BRAF
    Prager GW; Koperek O; Mayerhoefer ME; Muellauer L; Wrba F; Niederle B; Zielinski CC; Raderer M
    Thyroid; 2016 Oct; 26(10):1515-1516. PubMed ID: 27532222
    [No Abstract]   [Full Text] [Related]  

  • 12. Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy.
    Liu M; Jiang G; He W; Zhang P; Song N
    Ann Thorac Surg; 2011 Jul; 92(1):e11-2. PubMed ID: 21718818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
    Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
    Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
    Seeley AR; De Los Santos JF; Conry RM
    Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
    Brose MS; Cabanillas ME; Cohen EE; Wirth LJ; Riehl T; Yue H; Sherman SI; Sherman EJ
    Lancet Oncol; 2016 Sep; 17(9):1272-82. PubMed ID: 27460442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
    Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
    Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
    [No Abstract]   [Full Text] [Related]  

  • 17. Overcoming resistance in a
    Schmid T; Buess M
    Curr Oncol; 2018 Jun; 25(3):e217-e219. PubMed ID: 29962848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
    Joshi M; Rice SJ; Liu X; Miller B; Belani CP
    PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma.
    Sasaki H; Shimizu S; Tani Y; Shitara M; Okuda K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Lung Cancer; 2013 Oct; 82(1):51-4. PubMed ID: 23927882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.
    Protsenko SA; Semionova AI; Komarov YI; Aleksakhina SN; Ivantsov AO; Iyevleva AG; Imyanitov EN
    Invest New Drugs; 2015 Oct; 33(5):1136-43. PubMed ID: 26286452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.